Laura Bolaño G.

Reirradiation (#reRT) offers renewed hope for cancer recurrence—but comes with serious risks. Precision techniques, advanced imaging, and multidisciplinary care are essential. Don't miss this definitive review on this evolving treatment️: 🔗 acsjournals.onlinelibrary.wiley.com/doi/full/10.33… @OncoAlert

This is the treatment algorithm we’ve used during our discussion with @smitha42 for Colon/Colorectal Cancer! ✅ Early disease ✅ Biomarker & NGS driven approach ✅ Metastatic disease #OncTwitter #MedX @OncUpdates #gism

Gastric Cancer, A Review jamanetwork.com/journals/jama/… #GIpath

Resistance mechanisms in EGFR-mutant NSCLC are key for sequencing strategies. As highlighted by @LeXiuning, the MARIPOSA trial points to decreased in EGFR/MET-dependent resistance mechanisms, and no rise in TP53 or RB loss. With multiple new 2L and 3L options emerging, the landscape of targeted resistance may soon look very different. Watch her full talk ⬇️ lungsummit.org/targeted-thera…

Less Is More, But Me-Too Should Not Be the Strategy for Lung Cancer Treatment in 2026 A must-read, excellent article👇 ascopubs.org/doi/10.1200/ED…

Mutations in the tyrosine kinase domain of EGFR represent one of the most common druggable alterations in #NSCLC. This recent review provides a comprehensive clinical overview of the management of patients with EGFR-mutant NSCLC. acsjournals.onlinelibrary.wiley.com/doi/full/10.33… @OncoAlert @Alfdoc2

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up† @Annals_Oncology doi.org/10.1016/j.anno… 👉get the latest updates in CRC @myESMO @ASCO

🌟Updated RCC guidelines from @sitcancer @OncoAlert New expert recommendations refine the role of immunotherapy across disease stages in #RenalCellCarcinoma. 🧬 Key updates: 🔹 Adjuvant setting • ICI consolidation after nephrectomy in high-risk patients 👉 Patient selection remains critical 🔹 Advanced disease • ICI-based combinations as standard of care 👉 IO/IO and IO/TKI strategies continue to evolve 🔹 Personalization matters • Risk stratification + clinical context guide decisions 👉 “One-size-fits-all” is no longer acceptable ⚠️ Clinical challenge 👉 How do we balance benefit vs overtreatment in the adjuvant space? 💡 My take: We are moving toward precision immunotherapy in RCC 👉 The question is no longer if we use IO ➡️ but who truly benefits — and when 🔗 ow.ly/qyfG50Yzcml @sitcancer @arihakimi @brian_rini @_ShankarSiva @VincentWenxinXu @WesleyYipMD @TiansterZhang #KidneyCancer #RCC #Immunotherapy #OncoTwitter #GUOnc

Uterine cancer is the fourth most common cancer in women in the US, with an estimated 68 270 new cases and 14 450 cancer deaths projected to occur in 2026. 📄 This Review summarizes the epidemiology, clinical presentation, and diagnosis of endometrial cancer. ja.ma/4vJ6h6v

🫁 ADRIATIC: durvalumab in LS-SCLC. Durvalumab consolidation after cCRT improves OS and PFS across subgroups: chemo backbone, RT schedule, PCI use, and timing to randomization. No significant interactions. Consistent safety. Reinforces standard of care in LS-SCLC. PCI in the immunotherapy era? 📖 Journal of Thoracic Oncology DOI 👉🏻 doi.org/10.1016/j.jtho… #CánCare #SCLC #lcsm #immunotherapy

First line option for EGFR mut NSCLC . #oncology #NSCLC #medtwitter

MMR IHC Interpretation – Super Simple Quick Algorithm 🔥 Test the 4 proteins → All present? → pMMR (good) One or more missing? → dMMR (needs attention) Then follow the exact pattern of loss: MLH1 & PMS2 lost (most common) → Check BRAF & MLH1 methylation MSH2 & MSH6 lost → Likely Lynch Only MSH6 or only PMS2 lost → Possible Lynch Weird single losses (MSH2 alone or MLH1 alone) → Not possible, recheck! Key rule: Always read MMR as pairs, not single markers! (MLH1 protects PMS2 • MSH2 protects MSH6) Saves time in daily practice. Save & share! #MVOnco #Oncology #Pathology #MedEd

Advanced Triple-Negative Breast Cancer: Emerging Therapies and a Changing Treatment Landscape @ASCO Educational Book👇 ascopubs.org/doi/pdf/10.120…

Algorithm for Systemic Therapy in Early HR+/HER2- Breast Cancer (Recommendations in gray areas reflect my own clinical judgment— eg. olaparib and CDK4/6 sequence)

Let's review #TNT Total Neoadjuvant Treatment and Organ Preservation in #Rectal #Cancers. 1. PRODIGE23 - Induction CT + CRT 2. PROSPECT - No RT & Mid/upper only 3. OPRA - Induction CRT CT Ph2 4. OPERA - Contact Brachy Boost 5. MORPHEUS - HDR BT boost #crcsm #Oncology

🩺MAJOR SHIFT in Bladder Cancer Management For decades, cisplatin-ineligible MIBC patients faced poor outcomes with surgery alone. KEYNOTE-905 just changed the landscape. Perioperative EV + Pembrolizumab vs. Surgery: 📉 EFS HR: 0.40 ❤️ OS HR: 0.50 🔬 pCR: 57.1% (vs 8.6%) Is this the most impressive Forest Plot we've seen in GU Oncology recently? 🌳  Every subgroup favors the combination of EV + Pembro. For cisplatin-ineligible muscle-invasive bladder cancer, the debate is effectively over #BladderCancer #Oncology #MedTwitter #GUOnc @OncoAlert @ASCO @myESMO

Truck test passed ✅ #ADCs

Early & advanced stage MSI-H non-colorectal cancers: best management & challenges in 2025 ◾️In MSI-H/dMMR non-CRC GI cancers, perioOP paradigms are shifting. ◾️Neoadj. ICIs achieve pCR ~59–60% & MPR ~73–80%. ◾️Non-operative management is feasible (cCR ~65–76%, 12-mo gastrectomy-free survival ~64%), but pCR is not a validated surrogate for survival. ◾️Single biomarkers, such as IHC alone may be insufficient. ◾️The risk is not undertreatment, it is false certainty. ✅MSI-H/dMMR must be identified as early as possible to guide decision-making esmogastro.org/article/S2949-… @OncoAlert

High peak-dose corticosteroids used for irAE management in stage IV NSCLC are associated with worse OS and cancer-specific survival, while cumulative steroid dose and second-line immunosuppressants do not impact outcomes. esmoopen.com/article/S2059-…

DESTINY-Breast09, PATINA, HER2CLIMB-05… how to put it all together? How to treat HER2+ MBC in 2026? Nice Bridging the Gap piece by @ValenzaCarmine providing a framework for integrating the multiple new frontline option for HER2+ disease. ascopubs.org/doi/10.1200/JC…